Kenneth M Caldwell, MD
Orthopedic Surgery · Lafayette
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- 3
- 1 carrier
- Offices
- 2
- Since medical school
- 60 years
- University of California, San Francisco School of Medicine, 1966
On the public record
- Owns East Bay Special Surgery, LLC: Accreditation Lapsed
Offices
2 locations · Bass Medical Group · 292 clinicians in this group
Hospitals listed: Ou Health University of Oklahoma Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Caldwell’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A22558 · Current
Licensed to practise in California · since 1967 · expires 2027-05-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- East Bay Special Surgery, LLCAmbulatory Surgery Center · Oakland, CA3.83% owner since 2006 · accredited by IMQAccreditation Lapsed1 inspection, 1 with deficiencies · last 2015-11-19: Requirements Met
- The Surgery Center of Alta Bates Summit Medical CenterAmbulatory Surgery Center · Oakland, CAOwner · accredited by JCInitial Accreditation4 inspections, 4 with deficiencies · last 2017-07-27: Requirements Met
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- O U Medical CenterOklahoma City, OKAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of OU Health, which runs 2 hospitalsHome of Stephenson Cancer Center, a National Cancer Institute designated cancer centrePatients rate it 2 of 5 · 64% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.5 (1.27 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — In-hospital fall-associated fracture rate: 0.49 (0.31 to 0.67) · 10,386 cases, Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 6.71 (5.19 to 8.24) · 3,400 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.55 (14.53 to 24.57) · 1,302 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 6.6 (5.5 to 7.9) · 1,344 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.198, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.349, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.314, Oct 2024 – Sep 2025
See every measure and the patient survey for O U Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 1 worse of 7 measures. Safety: 3 better, 3 the same, 2 worse of 8 measures. Readmissions: 1 better, 6 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.5 (1.27 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.49 (0.31 to 0.67) · 10,386 cases | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 6.71 (5.19 to 8.24) · 3,400 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.55 (14.53 to 24.57) · 1,302 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.6 (5.5 to 7.9) · 1,344 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.198 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.349 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.314 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.46 (0.68 to 2.25) · 2,646 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 180.85 (143.45 to 218.26) · 284 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.1 · 151 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 14.2 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 261 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 371 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.5 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,857 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.3 (0.11 to 0.49) · 9,924 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.28 (0.79 to 3.77) · 1,346 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.49 to 3.78) · 3,335 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.53 (3.66 to 9.41) · 1,304 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.53 (0.22 to 2.83) · 942 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.51 (0.05 to 0.97) · 9,064 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.7 · 74 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.703 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.055 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.7 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 403 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -26.2 · 107 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -0.1 · 300 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.1 · 415 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.2 · 554 cases | None | Jul 2023 – Jun 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.8 (8.5 to 11.4) · 1,344 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 72 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.7 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.1 · 264 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.4 to 16.4) · 680 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 967 cases | No different | Jan 2024 – Dec 2024 |
What patients said (2,734 patients answered, 14% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$46,551
Medicare paid this office $46,551 for 86 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 69 | $16,311 | $112 |
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 18 | $15,801 | None |
| Aspiration and/or injection of fluid from large joint | 34 | $4,735 | $58 |
| New patient visit (45+ min) | 25 | $3,612 | $144 |
| X-ray of knee, 3 views | 21 | $1,521 | $43 |
See all 6 services
| Return visit (30+ min) | 69 | $16,311 | $112 |
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 18 | $15,801 | None |
| Aspiration and/or injection of fluid from large joint | 34 | $4,735 | $58 |
| New patient visit (45+ min) | 25 | $3,612 | $144 |
| X-ray of knee, 3 views | 21 | $1,521 | $43 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 20 | $71 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Aspiration and/or injection of fluid from large joint | 93 | 76 | 117 | 112 | 93 | 81 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
86 Original Medicare patients in 2024. Average age 79 · Women 54% · Health risk score 0.99. At or below the middle of the specialty; the typical orthopedic surgery clinician is at 1.13.
Conditions among them: High blood pressure 60% · Chronic kidney disease 26% · Cancer 20% · Atrial fibrillation 19% · Depression 15% · Coronary heart disease 13%.
The office billed $199,034, Medicare allowed $61,745 and paid $46,551; for 2,160 services of 15 kinds; $19,015 of it was for drugs given in the office and $27,536 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 86 | 2,160 | 79 | 0.99 | $199,034 | $46,551 |
| 2023 | 79 | 2,878 | 78 | 0.88 | $233,085 | $51,770 |
| 2022 | 101 | 3,246 | 78 | 0.94 | $300,260 | $72,253 |
| 2021 | 85 | 3,223 | 76 | 0.87 | $262,204 | $72,000 |
| 2020 | 84 | 2,716 | 76 | 0.89 | $120,801 | $51,358 |
| 2019 | 107 | 3,670 | 75 | 0.82 | $125,911 | $56,307 |
| 2018 | 126 | 4,872 | 75 | 0.92 | $106,147 | $48,632 |
| 2017 | 161 | 1,870 | 74 | 0.95 | $99,482 | $43,572 |
| 2016 | 237 | 2,480 | 75 | 0.94 | $334,839 | $112,442 |
| 2015 | 291 | 2,974 | 74 | 0.97 | $423,849 | $142,512 |
| 2014 | 309 | 3,098 | 74 | 0.88 | $446,605 | $153,065 |
| 2013 | 286 | 3,191 | 74 | 0.88 | $483,764 | $175,560 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 21 | $25,091 | None |
| Return visit (30+ min) | 62 | $12,941 | $113 |
| Aspiration and/or injection of fluid from large joint | 36 | $4,769 | $51 |
| New patient visit (45+ min) | 19 | $2,304 | $121 |
| X-ray of knee, 3 views | 17 | $725 | $40 |
| X-ray of shoulder, minimum of 2 views | 14 | $577 | $36 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $18 | None |
2022: 8 services
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 33 | $29,240 | None |
| Long return visit (40+ min) | 64 | $18,893 | $160 |
| New patient visit (60+ min) | 39 | $7,121 | $183 |
| Aspiration and/or injection of fluid from large joint | 46 | $6,023 | $54 |
| Return visit (30+ min) | 21 | $2,696 | $108 |
| X-ray of knee, 3 views | 33 | $1,763 | $42 |
| X-ray of shoulder, minimum of 2 views | 11 | $430 | $36 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 14 | $25 | None |
2021: 7 services
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 29 | $26,720 | None |
| Long return visit (40+ min) | 55 | $16,398 | $167 |
| Aspiration and/or injection of fluid from large joint | 54 | $6,371 | $54 |
| New patient visit (60+ min) | 25 | $4,518 | $181 |
| Return visit (30+ min) | 22 | $3,800 | $115 |
| X-ray of knee, 3 views | 27 | $1,597 | $42 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 29 | $40 | None |
2020: 9 services
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 27 | $23,158 | None |
| Short return visit (20+ min) | 54 | $5,539 | $64 |
| Aspiration and/or injection of fluid from large joint | 49 | $4,580 | $60 |
| Return visit (30+ min) | 32 | $3,459 | $91 |
| New patient visit (45+ min) | 14 | $1,750 | $125 |
| X-ray of knee, 3 views | 29 | $1,328 | $38 |
| X-ray of both knees while standing | 27 | $1,118 | $37 |
| X-ray of shoulder, minimum of 2 views | 13 | $570 | $34 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 22 | $100 | None |
2019: 9 services
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 18 | $9,947 | None |
| Short return visit (20+ min) | 65 | $8,162 | $63 |
| Return visit (30+ min) | 60 | $6,773 | $92 |
| Aspiration and/or injection of fluid from large joint | 62 | $4,929 | $53 |
| New patient visit (45+ min) | 31 | $3,858 | $124 |
| X-ray of knee, 3 views | 21 | $1,081 | $36 |
| X-ray of both knees while standing | 17 | $615 | $36 |
| X-ray of knee, 4 or more views | 12 | $521 | $37 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 37 | $218 | None |
2018: 7 services
| Short return visit (20+ min) | 62 | $7,164 | $62 |
| Return visit (30+ min) | 62 | $6,846 | $93 |
| New patient visit (45+ min) | 38 | $5,382 | $142 |
| Aspiration and/or injection of fluid from large joint | 54 | $4,819 | $51 |
| X-ray of knee, 4 or more views | 26 | $1,190 | $36 |
| X-ray of hip, 2-3 views | 14 | $566 | $40 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 44 | $328 | None |
2017: 11 services
| Short return visit (20+ min) | 107 | $9,605 | $60 |
| New patient visit (45+ min) | 41 | $5,182 | $126 |
| Aspiration and/or injection of fluid from large joint | 62 | $4,850 | $56 |
| Return visit (30+ min) | 47 | $4,557 | $93 |
| X-ray of knee, 3 views | 39 | $1,677 | $34 |
| X-ray of knee, 4 or more views | 29 | $1,244 | $36 |
| X-ray of hip, 2-3 views | 30 | $1,208 | $40 |
| Short return visit | 17 | $693 | $38 |
| X-ray of shoulder, minimum of 2 views | 17 | $508 | $25 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 40 | $142 | None |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 14 | $96 | None |
2016: 17 services
| Replacement of knee joint, both sides of knee | 20 | $25,278 | $1,149 |
| Short return visit (20+ min) | 202 | $19,836 | $53 |
| Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | 12 | $7,933 | None |
| Aspiration and/or injection of fluid from large joint | 68 | $5,279 | $48 |
| X-ray of knee, 3 views | 136 | $5,249 | $29 |
| Removal of knee cartilage using an endoscope | 12 | $5,150 | $429 |
| New patient visit (30+ min) | 51 | $4,161 | $82 |
| X-ray of both knees while standing | 95 | $3,184 | $31 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 27 | $2,487 | $69 |
| Short return visit | 47 | $1,961 | $34 |
| X-ray of hip, 2-3 views | 44 | $1,654 | $32 |
| X-ray of knee, 1-2 views | 48 | $1,378 | $27 |
| X-ray of pelvis, 1-2 views | 35 | $953 | $26 |
| X-ray of shoulder, minimum of 2 views | 31 | $940 | $25 |
| X-ray of both hips, 3-4 views | 14 | $566 | $40 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 56 | $442 | None |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 36 | $411 | None |
2015: 18 services
| Replacement of knee joint, both sides of knee | 23 | $27,787 | $1,158 |
| Short return visit (20+ min) | 230 | $24,757 | $59 |
| Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | 13 | $8,473 | None |
| New patient visit (30+ min) | 91 | $8,149 | $90 |
| Aspiration and/or injection of fluid from large joint | 78 | $7,662 | $54 |
| X-ray of knee, 3 views | 159 | $6,202 | $30 |
| Removal of both knee cartilages using an endoscope | 12 | $4,697 | $391 |
| X-ray of both knees while standing | 132 | $4,148 | $30 |
| X-ray of pelvis, 1-2 views | 125 | $3,532 | $24 |
| Short return visit | 48 | $2,370 | $38 |
| X-ray of hip on one side of body, 1 view | 72 | $2,201 | $23 |
| X-ray of knee, 1-2 views | 65 | $1,848 | $27 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 16 | $1,701 | $74 |
| X-ray of shoulder, minimum of 2 views | 26 | $878 | $27 |
| Aspiration and/or injection of fluid from large joint | 15 | $746 | $41 |
| X-ray of ribs of one side of body, minimum of 2 views | 14 | $552 | $32 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 59 | $552 | None |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 30 | $374 | None |
2014: 18 services
| Short return visit (20+ min) | 252 | $27,234 | $58 |
| Replacement of knee joint, both sides of knee | 23 | $26,980 | $1,173 |
| Replacement of thigh bone and hip joint with prosthesis | 12 | $14,391 | $1,107 |
| Aspiration and/or injection of fluid from large joint | 119 | $9,960 | $54 |
| Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | 16 | $7,848 | None |
| New patient visit (30+ min) | 87 | $7,458 | $86 |
| X-ray of knee, 3 views | 155 | $6,887 | $32 |
| Removal of both knee cartilages using an endoscope | 11 | $5,351 | $486 |
| Removal of knee cartilage using an endoscope | 11 | $4,663 | $424 |
| X-ray of both knees while standing | 120 | $4,218 | $34 |
| X-ray of pelvis, 1-2 views | 115 | $3,519 | $26 |
| Short return visit | 63 | $3,073 | $37 |
| X-ray of hip on one side of body, 1 view | 66 | $2,254 | $24 |
| Ultrasonic guidance for needle placement | 25 | $1,841 | $66 |
| X-ray of knee, 1-2 views | 54 | $1,609 | $29 |
| X-ray of shoulder, minimum of 2 views | 37 | $1,182 | $30 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 87 | $630 | None |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 31 | $286 | None |
2013: 20 services
| Replacement of knee joint, both sides of knee | 20 | $27,634 | $1,316 |
| Short return visit (20+ min) | 236 | $26,927 | $59 |
| Replacement of thigh bone and hip joint with prosthesis | 16 | $17,614 | $1,101 |
| Aspiration and/or injection of fluid from large joint | 137 | $12,590 | $58 |
| Ultrasonic guidance for needle placement | 34 | $7,737 | $198 |
| Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | 13 | $7,075 | None |
| Removal of both knee cartilages using an endoscope | 14 | $6,858 | $490 |
| X-ray of knee, 3 views | 139 | $6,293 | $35 |
| New patient visit (30+ min) | 70 | $5,964 | $85 |
| X-ray of both knees while standing | 112 | $4,110 | $35 |
| Short return visit | 69 | $3,838 | $36 |
| X-ray of pelvis, 1-2 views | 95 | $3,130 | $27 |
| X-ray of hip on one side of body, 1 view | 59 | $2,374 | $26 |
| X-ray of knee, 1-2 views | 56 | $1,888 | $29 |
| X-ray of shoulder, minimum of 2 views | 41 | $1,490 | $29 |
| Return visit (30+ min) | 15 | $1,432 | $95 |
| Complete ultrasound scan of joint | 12 | $1,213 | $101 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 89 | $742 | None |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 49 | $615 | None |
| Aspiration and/or injection of fluid from large joint | 12 | $543 | $42 |
Drugs they prescribed that Part D paid
$258
Pharmacies billed $258 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 19) in 2024. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
19 generic and 0 brand-name prescriptions · $258 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 19 | None | 0% (0) | 0% | $258 |
| 2023 | 24 | 13 | None | None | $242 |
| 2022 | 21 | 11 | 0% (0) | None | $625 |
| 2021 | 25 | None | 0% (0) | 0% | $558 |
| 2020 | 35 | 15 | None | None | $600 |
| 2019 | 63 | 28 | 32% (20) | 29% | $1,534 |
| 2018 | 89 | 41 | 27% (24) | None | $1,539 |
| 2017 | 71 | 45 | 27% (19) | None | $1,048 |
| 2016 | 75 | 45 | 28% (21) | 15% | $2,280 |
| 2015 | 134 | 71 | 28% (37) | 14% | $3,402 |
| 2014 | 84 | 44 | 24% (20) | None | $3,461 |
| 2013 | 78 | 51 | None | None | $6,112 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2021: 1 drug
| Celecoxib | 11 | $268 | $24 |
2019: 1 drug
| Voltaren | 13 | $713 | $55 |
2018: 2 drugs
| Hydrocodone-Acetaminophen | 14 | $146 | $10 |
| Amoxicillin | 16 | $70 | $4 |
2017: 1 drug
| Amoxicillin | 14 | $36 | $3 |
2015: 4 drugs
| Hydrocodone-Acetaminophen | 14 | $287 | $21 |
| Nabumetone | 22 | $230 | $10 |
| Oxycodone | 12 | $229 | $19 |
| Azithromycin | 11 | $109 | $10 |
2014: 1 drug
| Doxepin | 13 | $1,025 | $79 |
2013: 1 drug
| Doxepin | 12 | $1,308 | $109 |
Money from drug and device companies
$33 in 2021
A payment is not proof that care is biased.
| Pacira Therapeutics | Zilretta | $33 | 2 payments
|
See all 2 published payments
| Pacira Therapeutics | Meals · 2021-08-12 | Zilretta | $12 |
| Pacira Therapeutics | Meals · 2021-06-21 | Zilretta | $20 |
Professional record
- NPI
- 1457398224
- Licence
- CA A22558California A22558: Current · expires 2027-05-31
- Trained
- University of California, San Francisco School of Medicine, 1966 · 60 years ago
- Group
- Bass Medical Group
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A225581
- Taxonomy
- Orthopedic surgery (207X00000X)
- Mailing address
- Po Box 1298, Lafayette, CA, 94549
- NPI first listed
- 2006-06-01
- NPI last updated
- 2018-06-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 80 Grand Avenue, Oakland, CA, 94612